TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 2019-02-11
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.11%+1.21%+73.07%+128.44% 57.72B
-3.80%-6.24%+67.04%+86.36% 52.65B
+1.17%+5.83%+16.39%+468.18% 24.46B
+0.38%+1.33%-14.32%-11.76% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.12%+5.29%+44.50%-26.49% 17.8B
+3.46%+17.72%+206.66%+364.07% 17.29B
-6.73%+9.90%+36.04% - 15.28B
+2.79%+4.91%+29.26%+195.60% 14.35B
Average -0.70%+5.15%+55.67%+149.84% 26.96B
Weighted average by Cap. -1.20%+2.58%+57.52%+139.19%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock